NGAL is Downregulated in Oral Squamous Cell Carcinoma and Leads to Increased Survival, Proliferation, Migration and Chemoresistance
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Oral cancer is a major public health burden worldwide. The lack of biomarkers for early diagnosis has increased the difficulty in managing this disease. Recent studies have reported that neutrophil gelatinase-associated lipocalin (NGAL), a secreted glycoprotein, is upregulated in various tumors. In our study, we found that NGAL was significantly downregulated in primary malignant and metastatic tissues of oral cancer in comparison to normal tissues. The downregulation of NGAL was strongly correlated with both degree of differentiation and stage (I–IV); it can also serve as a prognostic biomarker for oral cancer. Additionally, tobacco carcinogens were found to be involved in the downregulation of NGAL. Mechanistic studies revealed that knockdown of NGAL increased oral cancer cell proliferation, survival, and migration; it also induced resistance against cisplatin. Silencing of NGAL activated mammalian target of rapamycin (mTOR)signaling and reduced autophagy by the liver kinase B1 (LKB1)-activated protein kinase (AMPK)-p53-Redd1 signaling axis. Moreover, cyclin-D1, Bcl-2, and matrix metalloproteinase-9 (MMP-9) were upregulated, and caspase-9 was downregulated, suggesting that silencing of NGAL increases oral cancer cell proliferation, survival, and migration. Thus, from our study, it is evident that downregulation of NGAL activates the mTOR pathway and helps in the progression of oral cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943 · cited 2×
“LKB1 is upstream of MPK, and, as AMPK is the only substrate, we analyzed the expr ssion of LKB1 and found that it was downregulated [25].”
BackgroundDowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933 · cited 2×
“, 2007 reported that metformin inhibited the activation of S6 via the AMP-activated protein kinase (AMPK) pathway [24].”
BackgroundThe mTOR Signalling Pathway in Human Cancer
Pópulo, H., Lopes, J. M., & Soares, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021886 · Cited by 830 · cited 1×
“In addition, in NGAL deficient cells, we observed that the expression of cyclin D1 is upregulated, which is regulated by the NF-κB/PI3K/mTOR pathways [22,23].”
BackgroundEllisen, L. W., Ramsayer, K. D., Johannessen, C. M., Yang, A., Beppu, H., Minda, K., Oliner, J. D., McKeon, F., & Haber, D. A. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00706-2 · Cited by 474
Cited by
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1
Klionsky, D. J., Abdel-Aziz, A. K., Abdelfatah, S., Abdellatif, M., Abdoli, A., Abel, S., Abeliovich, H., Abildgaard, M. H., Abudu, Y. P., Acevedo-Arozena, A., et al. (2021) · Autophagy · doi:10.1080/15548627.2020.1797280 · Cited by 2,897
Self-citationEmerging role of exosomes in cancer progression and tumor microenvironment remodeling
Paskeh, M. D. A., Entezari, M., Mirzaei, S., Zabolian, A., Saleki, H., Naghdi, M. J., Sabet, S., Khoshbakht, M. A., Hashemi, M., Hushmandi, K., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01305-4 · Cited by 563
Self-citationDatta, A., Deng, S., Gopal, V., Yap, K. C.-H., Halim, C. E., Lye, M. L., Ong, M. S., Tan, T. Z., Sethi, G., Hooi, S. C., et al. (2021) · Cancers · doi:10.3390/cancers13081882 · Cited by 184
Self-citationPotential of Zerumbone as an Anti-Cancer Agent
Girisa, S., Shabnam, B., Monisha, J., Fan, L., Halim, C. E., Arfuso, F., Ahn, K. S., Sethi, G., & Kunnumakkara, A. B. (2019) · Molecules · doi:10.3390/molecules24040734 · Cited by 161
Self-citationParama, D., Boruah, M., Yachna, K., Rana, V., Banik, K., Harsha, C., Thakur, K. K., Dutta, U., Arya, A., Mao, X., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118182 · Cited by 155
Self-citation
Metadata
- Authors
- Monisha, J., Roy, N. K., Padmavathi, G., Banik, K., Bordoloi, D., Khwairakpam, A. D., Arfuso, F., Chinnathambi, A., Alahmadi, T. A., Alharbi, S. A., Sethi, G., Kumar, A. P., & Kunnumakkara, A. B.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2018-07-10
- Volume
- 10
- Issue
- 7
- Pages
- 228
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2799475117
- Cited by
- 90
- References
- 5
- FWCI
- 9.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.